Antiparkinsonian drugs - drdhriti


Published on

A power point presentation on "Antiparkinsonian drugs" suitable for MBBS UG students

  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Famous sports personality Mohammed Ali (Casius clay) has been suffering from a disease.
  • 1. Muscle rigidity is a condition in which both the active and passive movements of a joint are restricted because of the abnormal, involuntary contraction of one or more muscles. 2.. 3. Rather than being a slowness in initiation (akinesia), bradykinesia describes a slowness in the execution of movement
  • Muscle rigidity is a condition in which both the active and passive movements of a joint are restricted because of the abnormal, involuntary contraction of one or more muscles
  • A  tremor  is an involuntary,[1] somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more body parts The tremor, which is classically seen as a “pill-rolling” action of the hands that may also affect the chin, lips, legs, and trunk, can be markedly increased by stress or emotions. Onset of parkinsonian tremor is generally after age 60. Movement starts in one limb or on one side of the body and usually progresses to include the other side. The tremor, which is classically seen as a “pill-rolling” action of the hands that may also affect the chin, lips, legs, and trunk, can be markedly increased by stress or emotions. Onset of parkinsonian tremor is generally after age 60. Movement starts in one limb or on one side of the body and usually progresses to include the other side. pill-rolling tremor   a parkinsonian tremor of the hand consisting of flexion and extension of the fingers in connection with adduction and abduction of the thumb
  • Rather than being a slowness in initiation (akinesia), bradykinesia describes a slowness in the execution of movement
  • DA fibres arising from SN tonically active, i.e. tonically inhibit striatum. Loss of inhibitory control leads to bradykinesia. GABA ergic fibres cause reduction of tonic influence of SN. Striatum also receives fibres from cortex ant thlumus – cholinergic fibres. . They are excitatory to striatum. Cholinergic and Dopaminergic fibrews exert opposing actions When DA fibres are reduced thyere is unbalanced overactivity of cholinergic fibres in striatum leading to symptoms of PD
  • Alpha-synuclein is a  synuclein   protein  of unknown function primarily found in  neural tissue , making up to 1% of all proteins in the  cytosol . [4]  It is predominantly expressed in the  neocortex ,  hippocampus ,  substantia nigra ,  thalamus , and  cerebellum . It is predominantly a neuronal protein, but can also be found in  glial cells .  Most cases of PD, HD etc are sporadic, but families with high incidence of these diseases have been identified In PD mutations in 4 different proteins have been identified: parkin - Proteins are tagged for degradation with a considerably small protein called  ubiquitin . The tagging reaction is catalyzed by enzymes called ubiquitin ligases . UCHL1( ubiquitin carboxyl-terminal esterase L1) gene participant in ubiquitin mediated degradation of peroteins in brain. DJ-1 mutations off DJ 1 proteins, a protein involved in neuronal response to stress. ENERGY METABOLOSM – reduction in complex 1 may be due to age related issues lead to damage in dopaminergic neurones. Additionally evidence on metabolism role comes from MPTP. It induces degeneration of nerves similar to that in idiopathic PD and its mechanism to impair mitochondrial metabolism in dopaminergic neurones. Genetic: Genetically determined PD are infrequent but, it is likely that an individual`s genetic background has an important role in the probability of acquiring this disease.
  • If slow emptying – prologed exposure of the drug to enzymes – degradation – less therapeutic conc.
  • eye blinking and throat clearing. [
  • Wearing off: In early therapy, duration of action exceeds plasma half life suggesting nigrostriatal retains capacity to store and release. On prolonged therapy – Buffering capacity is lost, patients motor state fluctuates with each dose. After each dose mobility improves for a period of time – 1-2hrs but rigidity and akinesia developes developes rapidly after e
  • Pyridoxine takes part in intermediary metabolism. It increases the metabolism of Levodopa by increasing the activity of peripheral decarboxylase enzyme and thereby low therapeutic concentration. An
  • Carbidopa does not cross bbb. Therefore, only peripheral decarboxylation is prevented and more production of Dopamine – more drug for CNS
  • Bromocriptine – ist dose phenomenon, hallucinations, vomiting, conjunctival injection
  • Restless legs syndrome  ( RLS ), also known as  Wittmaack-Ekbom's syndrome , and colloquially as  "the jimmylegs"  is a condition that is characterized by an irresistible urge to move one's body to stop uncomfortable or odd sensations. It most commonly affects the legs, but can also affect the arms or torso, and even  phantom limbs . [1]  Moving the affected body part modulates the sensations, providing temporary relief.
  • COMT and MAO are responsible for catabolism of levodopa and dopamine. COMT transferse a methyl group from the donor s-adenosyl-L-methionine, producing pharmacologically inactive 3 –o-methyl DOPA and 3-methoxytyramine. When l-dopa is administered 99% is catabolized and does not reach brain. Most are by peripheral decarboxylases (aromatic L-aminoacid decarboxylase, increases nausea and vomiting. Peripheral decarboxylase inhibitors will reduce dopamine formation but not block methylation by COMT. The principal action of COMT inhibitors is to block peripheral conversion of l-dopa to 3-o-methyl DOPA
  • MAO-A and MAO_B are two isoenzymes which oxidize monoamines . Both are present in periphery and intestinal mucosa. But, MAO-B is more in basal ganglia and responsible for degradation of dop-amine in brain. Non-specific MAO inhibitors – phenelzine, tranylcypromine , isocarboxazide
  • Antiparkinsonian drugs - drdhriti

    2. 2. Who is he?
    3. 3. Parkinsonism (PD) <ul><li>Extrapyramidal motor function disorder characterized by </li></ul><ul><li>Rigidity </li></ul><ul><li>Tremor </li></ul><ul><li>Hypokinesia/Bradykinesia </li></ul><ul><li>Impairment of postural balance - falling </li></ul>
    4. 4. Parkinsonism (PD) – contd. <ul><li>Rigidity </li></ul><ul><ul><li>Increased resistance to passive motion when limbs are moved through their range of motion – normal motions </li></ul></ul><ul><ul><ul><li>“Cogwheel rigidity” -- Jerky quality – intermittent catches of movement </li></ul></ul></ul><ul><ul><ul><li>Caused by sustained involuntary contraction of one or more muscles </li></ul></ul></ul><ul><ul><ul><ul><li>Muscle soreness; feeling tired & achy </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Slowness of movement due to inhibition of alternating muscle group contraction & relaxation in opposing muscle groups </li></ul></ul></ul></ul>
    5. 5. Parkinsonism (PD) – contd. <ul><li>Tremor </li></ul><ul><ul><li>First sign </li></ul></ul><ul><ul><li>Affects handwriting – trailing off at ends of words </li></ul></ul><ul><ul><li>More prominent at rest </li></ul></ul><ul><ul><li>Aggravated by emotional stress or increased concentration </li></ul></ul><ul><ul><li>“ Pill rolling” – rotary motion of thumb and forefinger </li></ul></ul><ul><ul><li>NOT essential tremor – intentional </li></ul></ul>
    6. 6. Parkinsonism (PD) – contd. <ul><li>Bradykinesia </li></ul><ul><ul><li>Loss of automatic movements: </li></ul></ul><ul><ul><ul><li>Blinking of eyes, swinging of arms while walking, swallowing of saliva, self-expression with facial and hand movements, lack of spontaneous activity, lack of postural adjustment </li></ul></ul></ul><ul><ul><ul><li>Results in: stooped posture, masked face, drooling of saliva, shuffling gait (festination); difficulty initiating movement </li></ul></ul></ul>
    7. 7. Parkinsonism (PD) - signs
    8. 8. Parkinsonism (PD) - signs
    9. 9. History – Parkinson`s disease <ul><li>Parkinson's disease was first formally described in &quot;An Essay on the Shaking Palsy,&quot; published in 1817 by a London physician named James Parkinson, but it has probably existed for many thousands of years. Its symptoms and potential therapies were mentioned in the Ayurveda, the system of medicine practiced in India as early as 5000 BC, and in the first Chinese medical text, Nei Jing, which appeared 2500 years ago </li></ul>
    10. 10. Parkinson`s disease - Pathophysiology <ul><li>The Basal Ganglia Consists of Five Large Subcortical Nuclei that Participate in Control of Movement: </li></ul><ul><ul><ul><li>Caudate Nucleus </li></ul></ul></ul><ul><ul><ul><li>Putamen </li></ul></ul></ul><ul><ul><ul><li>Globus Pallidus </li></ul></ul></ul><ul><ul><ul><li>Subthalamic Nucleus </li></ul></ul></ul><ul><ul><ul><li>Substantia Nigra </li></ul></ul></ul>
    11. 11. PD, Pathophysiology – contd. <ul><li>Striatum – Caudate Nucleus and Putamen </li></ul><ul><li>Substancia nigra pars compacta provide DA innervation to striatum </li></ul>
    12. 12. PD, Pathophysiology – contd. <ul><li>Degeneration of neurones in the substantia nigra pars compacta </li></ul><ul><li>Degeneration of nigrostriatal (dopaminergic) tract </li></ul><ul><li>Results in deficiency of Dopamine in Striatum - > 80% </li></ul>
    13. 13. PD, Pathophysiology – contd. <ul><li>Disruption of balance between Acetylcholine and Dopamine: </li></ul>Striatum Substancia Nigra DA fibres (Nigrostrital pathway) GABAergic fibres Cholinergic
    14. 14. PD, Pathophysiology – contd. <ul><li>Imbalance primarily between the excitatory neurotransmitter Acetylcholine and inhibitory neurotransmitter Dopamine in the Basal Ganglia </li></ul>ACh DA
    15. 15. PD - Etiology <ul><li>Cerebral atherosclerosis </li></ul><ul><li>Viral encephalitis </li></ul><ul><li>Side effects of several antipsychotic drugs (i.e., phenothiazides, butyrophenones, reserpine) </li></ul><ul><li>Pesticides, herbicides, industrial chemicals - contain substances that inhibit complex I in the mitochondria </li></ul>
    16. 16. Etiology of PD – contd. <ul><li>Genetic: </li></ul><ul><ul><li>α -sinuclein (synaptic protein) </li></ul></ul><ul><ul><li>Parkin (a ubiquitin protein ligase) </li></ul></ul><ul><ul><li>UCHL1 </li></ul></ul><ul><ul><li>DJ-1 protein </li></ul></ul><ul><li>Environmental triggers: </li></ul><ul><ul><li>Infectious agents – Encephalitis lethargica (epidemc) </li></ul></ul><ul><ul><li>Environmental toxins - MPTP (1- methyl -4- phenyl -1,2,3,6-tetrahydro pyridine ) </li></ul></ul><ul><ul><li>Acquired Brain Injury </li></ul></ul><ul><li>Excitotoxicity </li></ul><ul><ul><li>Glutamate, the normal excitatory transmitter in neurones in excess </li></ul></ul><ul><ul><li>Mediated by activated NMDA receptor </li></ul></ul><ul><ul><li>Ca++ overload – destructive processes </li></ul></ul><ul><li>Energy metabolism and aging: </li></ul><ul><ul><li>Reduction in function of complex 1 of mitochondrial-electron transport chain </li></ul></ul><ul><ul><li>MPTP </li></ul></ul><ul><li>Oxidative stress: Free radicals (`OH) – hydrogen peroxide and oxyradicals </li></ul>
    17. 17. PD - Mechanism Environmental Toxins Neuronal Metabolism Aging Free radical formation, oxidative stress, excitotoxicity Selective vulnerability of neuronal population DNA Damage Lipid peroxidation Protein Damage Cell Death
    18. 18. The Fighting agents (Drugs)
    19. 19. Treatment of PD
    20. 20. Classification of antiparkinsonian Drugs: <ul><li>Drugs acting on dopaminergic system : </li></ul><ul><ul><li>Dopamine precursors – Levodopa (l-dopa) </li></ul></ul><ul><ul><li>Peripheral decarboxylase inhibitors – carbidopa and benserazide </li></ul></ul><ul><ul><li>Dopaminergic agonists: Bromocriptyne, Ropinirole and Pramipexole </li></ul></ul><ul><ul><li>MAO-B inhibitors – Selegiline, Rasagiline </li></ul></ul><ul><ul><li>COMT inhibitors – Entacapone, Tolcapone </li></ul></ul><ul><ul><li>Dopamine facilitator - Amantadine </li></ul></ul><ul><li>Drugs acting on cholinergic system </li></ul><ul><ul><li>Central anticholinergics – Teihexyphenidyl (Benzhexol), Procyclidine, Biperiden </li></ul></ul><ul><ul><li>Antihistaminics – Orphenadrine, Promethazine </li></ul></ul>
    21. 21. Antiparkinsonian Drugs – contd. <ul><li>Dopamine and Tyrosine Are Not Used for Parkinson Disease Therapy, Why? </li></ul><ul><ul><li>Dopamine Doesn't Cross the Blood Brain Barrier </li></ul></ul><ul><ul><li>Huge amount of tyrosine decreases activity of rate limiting enzyme Tyrosine Hydroxylase </li></ul></ul>
    22. 22. Individual Drugs <ul><li>Levodopa: </li></ul><ul><ul><li>Single most effective agent in PD </li></ul></ul><ul><ul><li>Inert substance – decarboxylation to dopamine </li></ul></ul><ul><ul><li>95% is decarboxylated to dopamine in gut and liver </li></ul></ul><ul><ul><li>1 - 2% crosses BBB, taken up by neurones and DA is formed </li></ul></ul>
    23. 23. Levodopa (Pharmacological actions) <ul><li>CNS: </li></ul><ul><ul><li>Effective in Eliminating Most of the Symptoms of Parkinson Disease </li></ul></ul><ul><ul><li>Bradykinesia and Rigidity Respond Quickly </li></ul></ul><ul><ul><li>Reduction in Tremor Effect with Continued therapy </li></ul></ul><ul><ul><li>Handwritting , speech, facial expression and interest in life improves gradually </li></ul></ul><ul><ul><li>L Dopa less Effective in Eliminating Postural Instability and Shuffling Gait Meaning Other Neurotransmitters Are Involved in Parkinson Disease </li></ul></ul>
    24. 24. Levodopa (Pharmacological actions) - contd. <ul><li>Behavioural Effects: </li></ul><ul><ul><li>Partially Changes Mood by elevating mood, and increases Patient sense of well being </li></ul></ul><ul><ul><li>General alerting response </li></ul></ul><ul><ul><li>Disproportionate increase in sexual activity </li></ul></ul><ul><ul><li>No improvement in dementia </li></ul></ul>
    25. 25. Levodopa (Pharmacological actions) - contd <ul><li>CVS: </li></ul><ul><ul><li>Cardiac Stimulation Due to Beta adrenergic effect on Heart - Propranolol produces </li></ul></ul><ul><ul><li>Though stimulates peripheral adrenergic receptor – no rise in BP </li></ul></ul><ul><ul><li>Orthostatic Hypotension - some individuals – central DA and NA action </li></ul></ul><ul><ul><li>In elderly cardiovascular problems - transient tachycardia, cardiac arrhythmias and hypertension </li></ul></ul><ul><ul><li>Tolerance to CVS action develops within few weeks </li></ul></ul><ul><li>CTZ: DA receptors cause stimulation – nausea and vomiting – tolerance </li></ul><ul><li>Endocrine: Decrease in Prolactin level and increase in GH release </li></ul>
    26. 26. Levodopa - Pharmacokinetics <ul><li>Absorbed rapidly from small intestine – aromatic amino acid transport system </li></ul><ul><li>High First Pass Effect – large doses </li></ul><ul><li>Peak plasma conc. 1-2 hrs and half life - 1 to 3 Hrs </li></ul><ul><li>Depends on gastric emptying and pH </li></ul><ul><li>Competition for amino acids present in food competes for the carrier </li></ul><ul><li>Metabolized in liver and peripherally - secreted in urine unchanged or conjugated with glucoronyl sulfate </li></ul><ul><li>Central entry into CNS (1%) - mediated by membrane transporter for aromatic amino acids – competition with dietary protein </li></ul><ul><li>In CNS – Decarboxylated and DA is formed – therapeutic effectiveness </li></ul><ul><li>Transport back by presynaptic uptake or metabolized by MAO and COMT </li></ul>
    27. 27. Levodopa (Pharmacokinetics) – contd.
    28. 28. Levodopa (adverse effects) -Initial Therapy: <ul><ul><li>Nausea and vomiting - 80% of patients </li></ul></ul><ul><ul><li>Postural hypotension – 30 % of patients tolerance develops </li></ul></ul><ul><ul><li>Cardiac arrhythmias - due to beta adrenergic action </li></ul></ul><ul><ul><li>Exacerbation of angina </li></ul></ul>
    29. 29. Levodopa (adverse effects) - Initial Therapy: <ul><li>Abnormal movements: Facial tics, grimacing, tongue thrusting, choreoathetoid movements </li></ul><ul><li>Behavioural effects: </li></ul><ul><ul><li>20 to 25% of Population </li></ul></ul><ul><ul><li>Trouble in Thinking (Cognitive Effects) </li></ul></ul><ul><ul><li>L Dopa can induce: Anxiety, psychosis, confusion, hallucination, delusion </li></ul></ul><ul><ul><li>Hypomania - Inappropriate Sexual Behavior; &quot;Dirty Old Man&quot;, &quot;Flashers“ </li></ul></ul><ul><li>- Drug Holiday </li></ul>
    30. 30. Levodopa (adverse effects) - Prolonged therapy – contd. <ul><li>Fluctuation in Motor Performance: </li></ul><ul><ul><li>Initial therapy – each dose - good duration of action </li></ul></ul><ul><ul><li>Prolonged therapy – “ buffering” capacity is lost – each dose causes fluctuation of motor state - each dose has short duration of action– short therapeutic effect (1 – 2 Hrs) – bradykinesia and rigidity comes back quickly </li></ul></ul><ul><ul><li>Increase in dose and frequency – DYSKINESIA – excessive abnormal involuntary movements </li></ul></ul><ul><ul><li>Dyskinesia often with high plasma conc. of levodopa </li></ul></ul><ul><ul><li>Dyskinesia = Bradykinesia and Rigidity in terms of patient comfortness </li></ul></ul><ul><ul><li>&quot;On/off&quot; Phenomenon </li></ul></ul><ul><ul><li>Like a Light Switch: Without Warning </li></ul></ul>
    31. 31. Levodopa (adverse effects) - Prolonged therapy – contd. <ul><li>Denervation Supersensitivity: </li></ul><ul><ul><li>In Basal Ganglia – destruction of Dopaminergic Neurons –increase in Dopamine Receptors postsynaptically </li></ul></ul><ul><ul><li>L Dopa Therapy - increase Dopamine at synaptic Cleft - but too many Receptors - Denervation Supersensitivity </li></ul></ul><ul><ul><li>Effect - Increased Postsynaptic Transmission </li></ul></ul><ul><ul><li>Initial disappearance of Parkinson Syndrome </li></ul></ul><ul><ul><li>Onset of Dyskinesia </li></ul></ul>
    32. 32. Levodopa – Drug Interactions <ul><li>Pyridoxine – abolishes therapeutic effect of levodopa </li></ul><ul><li>Antipsychotic Drugs – Phenothiazines, butyrophenones block the action of levodopa by blocking DA receptors. </li></ul><ul><li>Antidopeminergic – domperidone abolishes nausea and vomiting </li></ul><ul><li>Reserpine – blocks levodopa action by blocking vesicular uptake </li></ul><ul><li>Anticholinergics – synergistic action but delayed gastric emptying – reduced effect of levodopa </li></ul><ul><li>Nonspecific MAO Inhibitors – Prevents degradation of peripherally synthesized DA – hypertensive crisis by the tyramine-cheese effect (tyramine is found in cheese, coffee, beer, pickles and chocolate), when given to a person taking a MAO Inhibitor - tyramine is not broken down - tremendous release of Norepinephrine) </li></ul>
    33. 33. Levodopa Vs Peripheral decarboxylase inhibitors <ul><li>Carbidopa and Benserazide: </li></ul><ul><ul><li>In practice, almost always administered </li></ul></ul><ul><ul><li>Do not penetrate BBB </li></ul></ul><ul><ul><li>Do not inhibit conversion of l-dopa to DA in brain </li></ul></ul><ul><ul><li>Co-administration of Carbidopa - will decrease metabolism of l-dopa in GI Tract and peripheral tissues - increase l-dopa conc in CNS - meaning decrease l-dopa dose and also control of dose of l-dopa </li></ul></ul>
    34. 34. Levodopa Vs Peripheral decarboxylase inhibitors – contd. <ul><li>Benefits: </li></ul><ul><ul><li>Plasma t 1/2 – prolonged </li></ul></ul><ul><ul><li>Dose of levodopa – 30% reduction </li></ul></ul><ul><ul><li>Reduction in systemic complications </li></ul></ul><ul><ul><li>Nausea and Vomiting – less </li></ul></ul><ul><ul><li>Cardiac – minimum complications </li></ul></ul><ul><ul><li>Pyridoxine reversal of levodopa – do not occur </li></ul></ul><ul><ul><li>On/Off effect – minimum </li></ul></ul><ul><ul><li>Better overall improvement of patient </li></ul></ul>
    35. 35. Levodopa Vs Peripheral decarboxylase inhibitors – contd.
    36. 36. Dopamine receptors agonists <ul><li>Bromocriptine, pergolide, Ropinirole and Pramipexole: </li></ul><ul><ul><li>Bromocryptine – D 2 agonist and D 1 partial agonist </li></ul></ul><ul><ul><li>Pergolide – Both D 1 and D 2 </li></ul></ul><ul><ul><li>Newer (Pramipexole and Ropinirole –D 2 and D 3 </li></ul></ul>
    37. 37. Dopamine receptors agonists <ul><li>Bromocriptine is a ergot derivative </li></ul><ul><li>All four drugs are well absorbed orally </li></ul><ul><li>Similar therapeutic action </li></ul><ul><li>Relieves clinical symptoms of PD </li></ul><ul><li>Duration of action is longer than L-dopa (8-16 Hrs) </li></ul><ul><li>Effective in patients with on/off phenomenon </li></ul><ul><li>Side effects like confusions, hallucinations simmilar to l-dopa </li></ul><ul><li>Ist dose effect – orthostatic hypotension </li></ul>
    38. 38. Dopamine receptors agonists <ul><li>Newer Vs Older DA receptor agonists </li></ul><ul><ul><li>More tolerable – Nausea, vomiting and fatigue </li></ul></ul><ul><ul><li>Dose titration - Slow upward adjustment of dose </li></ul></ul><ul><ul><li>Newer ones – Somnolence (Irresistible Sleepiness) </li></ul></ul>
    39. 39. Dopamine receptors agonists – contd. <ul><li>Initial treatment of PD: Newer drugs are used now especially children: </li></ul><ul><ul><li>Longer duration of action than L-dopa – less chance of on/off effect and dyskinesia </li></ul></ul><ul><ul><li>No oxidative stress and thereby loss of dopeminergic neurons </li></ul></ul><ul><ul><li>Reduced rate of motor fluctuation </li></ul></ul><ul><ul><li>Restless leg syndrome/Wittmaack-Ekbom's syndrome/the jimmylegs - Ropinirole </li></ul></ul>
    40. 40. COMT inhibitors: Entacapone and Tolcapone Entacapone Tolcapone Carbidopa
    41. 41. Entacapone and Tolcapone – contd. <ul><li>Reduce wearing off phenomenon in patients with levodopa and carbidopa </li></ul><ul><li>Common adverse effects simmilar to levodopa </li></ul><ul><li>Entacapone: </li></ul><ul><ul><li>Peripheral action on COMT </li></ul></ul><ul><ul><li>Duration of action short (2 hrs) </li></ul></ul><ul><ul><li>No hepatoxicity </li></ul></ul><ul><li>Tolcapone: </li></ul><ul><ul><li>Central and peripheral inhibition of COMT </li></ul></ul><ul><ul><li>Long duration of action – 2 to 3 times daily </li></ul></ul><ul><ul><li>Hepatoxicity (2%) </li></ul></ul><ul><li>Both are available in fixed dose combinations with levodopa/carbidopa </li></ul>
    42. 42. MAO-B inhibitors: Selegiline <ul><li>Selective and irreversible MAO-B inhibitor </li></ul><ul><li>MAO-A and MAO-B are present in periphery and intestinal mucosa – inactivate monoamines </li></ul><ul><li>MAO-B is also present in Brain and platelets </li></ul><ul><li>Low dose of Selegiline (10 mg) – irreversible inhibition of the enzyme </li></ul><ul><ul><li>Does not inhibit peripheral metabolism of dietary amines, so safely levodopa can be taken </li></ul></ul><ul><ul><li>No lethal potentiation of CA action – no cheese reaction, unlike non-specific inhibitors </li></ul></ul><ul><ul><li>Dose more than 10 mg – inhibition of MAO-A should be avoided. </li></ul></ul>
    43. 43. Selegiline – contd. <ul><li>Selegiline can be used in mild early PD </li></ul><ul><li>Adjunct to levodopa in early cases </li></ul><ul><ul><li>Prolong levodopa action </li></ul></ul><ul><ul><li>Reduction in dose of levodopa </li></ul></ul><ul><ul><li>Reduces motor fluctuations </li></ul></ul><ul><ul><li>Decreases wearing off phenomenon </li></ul></ul><ul><ul><li>Advance cases of on/off – not improved </li></ul></ul><ul><ul><li>Levodopa side effects (hallucinations) etc, worsens </li></ul></ul><ul><li>Neuroprotective properties – protect dopamine from free radical and oxidative stress </li></ul><ul><li>Protects from MPTP induce parkinsonism </li></ul>
    44. 44. Dopamine facilitators: Amantadine <ul><li>Antiviral agent </li></ul><ul><li>Several pharmacological action </li></ul><ul><li>Alter the dopamine release in striatum and has anticholinergic properties </li></ul><ul><li>Blocks NMDA glutamate receptors </li></ul><ul><li>Used as initial therapy of mild PD </li></ul><ul><li>Also helpful in dose related fluctuations and dyskinesia </li></ul><ul><li>Dose is 100 mg twice daily </li></ul><ul><li>Dizziness, lethargy and anticholinergic effects – mild side effects </li></ul>
    45. 45. Central Anticholinergics: Teihexyphenidyl (Benzhexol), Procyclidine, Biperiden <ul><li>These are the Drugs with higher central : peripheral anticholinergic action than Atropine </li></ul><ul><li>Reduce unbalanced cholinergic activity in striatum </li></ul><ul><li>Duration af action is 4-8 Hrs </li></ul><ul><li>Tremor is benefited more than rigidity – least to hypokinesia </li></ul><ul><li>Overall activity is lower than levodopa </li></ul><ul><li>Used in mild cases and when levodopa is contraindicated </li></ul><ul><li>Combination with levodopa to reduce its dose </li></ul><ul><li>Also used in Drug Induced Parkinsonism </li></ul><ul><li>Antihistaminic like Orphenadrine, Promethazine are used in PD for their anticholinergic action </li></ul>
    46. 46. Drug Induced Parkinsonism: <ul><li>Antipsychotics: Chlorpromazine, Fluphen-zine and Haloperidol </li></ul><ul><li>Antihypertensive like Reserpine </li></ul><ul><li>Antiemetics: Metochlopramide (Reglan) and Prochlorperazine (Compazine), </li></ul><ul><li>Not associated with loss of nerve cells in the substantia nigra </li></ul><ul><li>Differ from the permanent PD associated with the nerve toxin MPTP - loss of nerve cells in the substantia nigra. </li></ul>
    47. 47. Points to remember: <ul><li>None of the present drugs alter basic pathology of PD </li></ul><ul><li>Initiation of levodopa therapy should be delayed as far as possible </li></ul><ul><li>Monotherapy with Selegiline or anticholinergics or amantadine - in mild cases. Newer Drugs like Ropirinole etc. can also be used </li></ul><ul><li>In deterioration phase – levodopa and carbidopa combination, not levodopa alone. Slow and careful initiation </li></ul><ul><li>Benefit from drug therapy wears off – dyskinesia develops. Later on/off phenomenon develops – patient problem becomes same as with drugs or without drugs </li></ul><ul><li>Peripheral decarboxylase inhibitors decreases early, but not late complications </li></ul><ul><li>DA agonists like Ropinirole are used to supplement levodopa to prevent on/off phenomenon and reduce levodopa dose </li></ul><ul><li>COMT inhibitors like entacapone are added to levodopa carbidopa to prolong their action and to reduce on/off </li></ul>
    48. 48. Newer Fields: <ul><ul><li>Neurotrophic proteins--These appear to protect nerve cells from the premature death that prompts Parkinson's. One hurdle is getting the proteins past the blood-brain barrier. </li></ul></ul><ul><ul><li>Neuroprotective agents--Researchers are examining naturally occurring enzymes that appear to deactivate &quot;free radicals,&quot; </li></ul></ul><ul><ul><li>Neural tissue transplants </li></ul></ul><ul><ul><li>Genetic engineering--Scientists are modifying the genetic code of individual cells to create dopamine-producing cells from other cells, such as those from the skin </li></ul></ul>
    49. 49. Thank you / Khublei
    50. 50. Wiring of Basal Ganglia
    51. 51. Basal Ganglia in PD